首页> 外文期刊>Autoimmunity >Development of novel therapies for MG: Studies in animal models
【24h】

Development of novel therapies for MG: Studies in animal models

机译:MG新疗法的发展:动物模型研究

获取原文
获取原文并翻译 | 示例
           

摘要

Experimental myasthenia gravis (MG) in animals, and in particular experimental autoimmune MG in rodents, serves as excellent models to study possible novel therapeutic modalities for MG. The current treatments for MG are based on cholinesterase inhibitors, general immunosuppressants, and corticosteroids, broad immunomodulatory therapies such as plasma exchange or intravenous immunoglobulins (IVIGs), and thymectomy for selected patients. This stresses the need for immunotherapies that would specifically or preferentially suppress the undesirable autoimmune response without widely affecting the entire immune system as most available treatments do. The available animal models for MG enable to perform preclinical studies in which novel therapeutic approaches can be tested. In this review, we describe the different therapeutic approaches that were so far tested in experimental models of MG and discuss their underlying mechanisms of action. These include antigen - acetylcholine receptor (AChR)-dependent treatments aimed at specifically abrogating the humoral and cellular anti-AChR responses as well as immunomodulatory approaches that could be used either alone or in conjunction with antigen-specific treatments or alternatively serve as steroid sparing agents. The antigen-specific treatments are based on fragments or peptides derived from the acetylcholine receptor (AChR) that would theoretically deviate the anti-AChR autoimmune response away from the muscle target or on ways to target AChR-specific T- and B- cell responses or antibodies. The immunomodulatory modalities include cell-based and non-cell-based ways to affect or manipulate key players in the autoimmune process such as regulatory T cells, dendritic cells, cytokine networks, and chemokine and costimulatory signaling as well as complement pathways. We also describe approaches that attempt to affect the cholinergic balance, which is impaired at the neuromuscular junction. In addition to enabling to test the feasib
机译:实验性Myasthenia invis(mg)在动物中,特别是啮齿动物的实验性自身免疫mg,用于研究Mg可能的新的治疗方式。 Mg的目前的处理基于胆碱酯酶抑制剂,通用免疫抑制剂和皮质类固醇,宽免疫调节治疗,例如血浆交换或静脉内免疫球蛋白(IVIG),以及所选患者的胸膜切除术。这强调需要专门或优先抑制不良自身免疫反应的免疫疗法,而不会因大多数可用治疗而广泛影响整个免疫系统。用于MG的可用动物模型使得能够进行临床前研究,其中可以测试新的治疗方法。在本文中,我们描述了到目前为止在MG的实验模型中测试的不同治疗方法,并讨论了他们的潜在的行动机制。这些包括抗原 - 乙酰胆碱受体(ACHR) - 依赖性治疗,其旨在特异性地消除了体液和细胞抗ACHR反应以及可单独使用或与抗原特异性处理结合使用的免疫调节方法或者作为类固醇备件剂。抗原特异性治疗基于衍生自乙酰胆碱受体(ACHR)的片段或肽,其理论上将偏离抗ACHR自身免疫反应远离肌肉靶或靶向靶向ACHR特异性T-和B细胞反应或抗体。免疫调节模式包括基于细胞和基于非细胞的方式,以影响或操纵自身免疫过程中的关键参与者,例如调节性T细胞,树突细胞,细胞因子网络和趋化因子以及共同刺激信号传导以及补体途径。我们还描述了试图影响胆碱能平衡的方法,这在神经肌肉交叉点受到损害。除了能够测试feasib

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号